+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Multiple Myeloma Drug Market Research Report by Drug, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4968786
  • Report
  • July 2021
  • Region: Global
  • 196 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Multiple Myeloma Drug Market will Grow to USD 28.59 Billion by 2026, at a CAGR of 7.85%

FEATURED COMPANIES

  • 7 Eleven
  • Actavis Pharma Company
  • Bristol-Myers Squibb
  • Hospira, Inc.
  • Novartis
  • Pfizer
The Global Multiple Myeloma Drug Market size was estimated at USD 18.16 Billion in 2020 and expected to reach USD 19.53 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 7.85% to reach USD 28.59 Billion by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Multiple Myeloma Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug, the Multiple Myeloma Drug Market was examined across Histone Deacetylase Inhibitors, Immunomodulating Agents, Monoclonal Antibodies, and Proteasome Inhibitors.
  • Based on Distribution, the Multiple Myeloma Drug Market was examined across Hospital Pharmacy, Online Channel, and Retail Pharmacy.
  • Based on Geography, the Multiple Myeloma Drug Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas was further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific was further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa was further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. This ongoing research amplifies this research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Multiple Myeloma Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Multiple Myeloma Drug Market, including 7 Eleven, Accord Healthcare S.L.U., Accurex Health Care Manufacturing Inc., Actavis Pharma Company, Bayer, Bristol-Myers Squibb, Celgene Corporation, Hospira, Inc., Janssen Pharmaceuticals, Inc., Johnson & Johnson, New Haven Pharmaceuticals, Inc., Novartis, Onyx Pharmaceuticals, Pfizer, Sagent Pharmaceuticals, Sandoz, Takeda Pharmaceuticals, and Whole Foods Market, Inc.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Multiple Myeloma Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Multiple Myeloma Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Multiple Myeloma Drug Market?
4. What is the competitive strategic window for opportunities in the Global Multiple Myeloma Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Multiple Myeloma Drug Market?
6. What is the market share of the leading vendors in the Global Multiple Myeloma Drug Market?
7. What modes and strategic moves are considered suitable for entering the Global Multiple Myeloma Drug Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 7 Eleven
  • Actavis Pharma Company
  • Bristol-Myers Squibb
  • Hospira, Inc.
  • Novartis
  • Pfizer
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Drug Outlook
3.4. Distribution Outlook
3.5. Geography Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased indication and prevalence of Multiple Myeloma
5.1.1.2. Attractive reimbursement policies supporting treatments in developed countries
5.1.1.3. Increased drug availability along with approvals for generics
5.1.2. Restraints
5.1.2.1. Stringent drug approval process
5.1.3. Opportunities
5.1.3.1. Collaborating product development and drug trials and commercialization
5.1.3.2. Targeted therapy and adoption of Corticosteroids
5.1.4. Challenges
5.1.4.1. Potential side effects
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Multiple Myeloma Drug Market, by Drug
6.1. Introduction
6.2. Histone Deacetylase Inhibitors
6.3. Immunomodulating Agents
6.4. Monoclonal Antibodies
6.5. Proteasome Inhibitors

7. Multiple Myeloma Drug Market, by Distribution
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Online Channel
7.4. Retail Pharmacy

8. Americas Multiple Myeloma Drug Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Multiple Myeloma Drug Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Thailand

10. Europe, Middle East & Africa Multiple Myeloma Drug Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. 7 Eleven
12.2. Accord Healthcare S.L.U.
12.3. Accurex Health Care Manufacturing Inc.
12.4. Actavis Pharma Company
12.5. Bayer
12.6. Bristol-Myers Squibb
12.7. Celgene Corporation
12.8. Hospira, Inc.
12.9. Janssen Pharmaceuticals, Inc.
12.10. Johnson & Johnson
12.11. New Haven Pharmaceuticals, Inc.
12.12. Novartis
12.13. Onyx Pharmaceuticals
12.14. Pfizer
12.15. Sagent Pharmaceuticals
12.16. Sandoz
12.17. Takeda Pharmaceuticals
12.18. Whole Foods Market, Inc.

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2020 VS 2026 (USD BILLION)
FIGURE 2. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2020 (USD BILLION)
FIGURE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2020 (USD BILLION)
FIGURE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2020 (USD BILLION)
FIGURE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET: MARKET DYNAMICS
FIGURE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2020 VS 2026 (%)
FIGURE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2020 VS 2026 (USD BILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2026
FIGURE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2026 (USD BILLION)
FIGURE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATING AGENTS, 2018-2026 (USD BILLION)
FIGURE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATING AGENTS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2026 (USD BILLION)
FIGURE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 17. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2026 (USD BILLION)
FIGURE 18. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 19. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (%)
FIGURE 20. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (USD BILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2026
FIGURE 22. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2026 (USD BILLION)
FIGURE 23. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 24. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE CHANNEL, 2018-2026 (USD BILLION)
FIGURE 25. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE CHANNEL, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 26. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2026 (USD BILLION)
FIGURE 27. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 28. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 29. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 31. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 32. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 33. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 34. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 35. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 36. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 37. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 38. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 39. AUSTRALIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 40. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 41. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 42. INDONESIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 43. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 44. MALAYSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 45. PHILIPPINES MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 46. SINGAPORE MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 47. SOUTH KOREA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 48. THAILAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 49. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 50. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 51. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 52. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 53. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 54. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 55. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 56. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 57. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 58. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 59. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 60. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 61. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 62. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 63. GLOBAL MULTIPLE MYELOMA DRUG MARKET: FPNV POSITIONING MATRIX
FIGURE 64. GLOBAL MULTIPLE MYELOMA DRUG MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 65. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL MULTIPLE MYELOMA DRUG MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL MULTIPLE MYELOMA DRUG MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATING AGENTS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE CHANNEL, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 13. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 14. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 15. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 16. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 17. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 18. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 19. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 20. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 21. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 22. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 23. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 24. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 25. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 26. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 27. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 28. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 29. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 30. AUSTRALIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 31. AUSTRALIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 32. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 33. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 34. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 35. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 36. INDONESIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 37. INDONESIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 38. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 39. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 40. MALAYSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 41. MALAYSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 42. PHILIPPINES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 43. PHILIPPINES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 44. SINGAPORE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 45. SINGAPORE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 46. SOUTH KOREA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 47. SOUTH KOREA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 48. THAILAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 49. THAILAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 51. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 52. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 53. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 54. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 55. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 56. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 57. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 58. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 59. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 60. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 61. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 62. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 63. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 64. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 65. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 66. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 67. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 68. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 69. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 70. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 71. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 72. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 73. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 74. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 75. GLOBAL MULTIPLE MYELOMA DRUG MARKET: SCORES
TABLE 76. GLOBAL MULTIPLE MYELOMA DRUG MARKET: BUSINESS STRATEGY
TABLE 77. GLOBAL MULTIPLE MYELOMA DRUG MARKET: PRODUCT SATISFACTION
TABLE 78. GLOBAL MULTIPLE MYELOMA DRUG MARKET: RANKING
TABLE 79. GLOBAL MULTIPLE MYELOMA DRUG MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 80. GLOBAL MULTIPLE MYELOMA DRUG MARKET: MERGER & ACQUISITION
TABLE 81. GLOBAL MULTIPLE MYELOMA DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 82. GLOBAL MULTIPLE MYELOMA DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 83. GLOBAL MULTIPLE MYELOMA DRUG MARKET: INVESTMENT & FUNDING
TABLE 84. GLOBAL MULTIPLE MYELOMA DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 85. GLOBAL MULTIPLE MYELOMA DRUG MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • 7 Eleven
  • Accord Healthcare S.L.U.
  • Accurex Health Care Manufacturing Inc.
  • Actavis Pharma Company
  • Bayer
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Hospira, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson
  • New Haven Pharmaceuticals, Inc.
  • Novartis
  • Onyx Pharmaceuticals
  • Pfizer
  • Sagent Pharmaceuticals
  • Sandoz
  • Takeda Pharmaceuticals
  • Whole Foods Market, Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll